FT : Swatch and Audemars Piguet’s collab provides a much-needed pop

Swatch and Audemars Piguet’s collab provides a much-needed pop
The launch may not have gone quite according to plan, but such tie-ups are a good way to inject some buzz into the market

This month’s launch of the “Royal Pop” collaboration between Swatch and Audemars Piguet — two Swiss watch brands at opposite ends of the luxury spectrum — attracted the kind of publicity the companies might have preferred to do without. But in reality, it is good news for them, and a sign of the times for the luxury sector more broadly.

The launch of the pocket watch, in Swatch’s trademark plastic but reminiscent of Audemars Piguet’s Royal Oak flagship, did not run smoothly. There were scuffles and worse in queues outside Swatch stores in London, New York, Paris and beyond, with police in some places using tear gas and pepper spray to subdue the crowds. Videos on social media showed people in hoodies fighting over the chance to buy a Royal Pop pocket watch retailing at up to £350, potentially hoping to flip it on secondary markets for a good 10 times that amount.

Still, for Swatch Group, the new product will turn a neat profit. The cost of producing each pocket watch, according to Bernstein analysts, is no more than 20 per cent of its retail price, with royalties to Audemars Piguet likely to be about the same. This still leaves a 60 per cent gross margin that, taking the lower end of estimated sales of between 500,000 and 1mn units, will deliver at least SFr100mn ($125mn) to Swatch Group’s bottom line. That’s about 40 per cent of this year’s forecast net income.



Swatch — which makes all its watches in Switzerland — can claim to have saved the national industry at least twice: from the quartz movement revolution and from the smartphone, which made wristwatches redundant for many people. Maybe this fresh iteration will help defend it a little longer.

For Audemars Piguet, the upside is less clear. It is true that high-end watchmakers do not have the option of offering cheaper “entry-level” products in the way that apparel or cosmetics makers can. So it is vaguely possible that the Royal Pop will serve that function: perhaps some young buyers will one day buy the Royal Oak for 100 times the price. But equally, some of today’s Royal Oak devotees may not love the idea of entry-level fashionistas getting a piece of their exclusive brand.

The tie-up, in any case, showcases a wider trend in the luxury sector. Fashion and luxury collaborations, already a widespread phenomenon, are a good way to inject some buzz into a market that’s been short of both ideas and consumer appetite. And perhaps the weirder, wilder and more debated, the better for everyone involved.

Barron's : Live Longer and Better. Does Medicine’s New Obsession Really Work?

Live Longer and Better. Does Medicine’s New Obsession Really Work?
The longevity industry is booming with high-tech tests, drugs, and medical devices. What to know for your health—and personal finances.

Abby Miller Levy thinks a lot about what really pays off in healthcare.
Co-founder of venture-capital firm Primetime Partners, she invests in start-ups involved in everything from dementia prevention to “bioidentical pellet therapy” for better libido. Only after crunching the numbers, interviewing experts, and analyzing all of the angles do she and her partners invest.

Miller Levy also takes a data-driven approach to her own health. She has undergone advanced imaging and does regular blood tests and data analysis. Her physician knows the true biological age of her vital organs; if something turns up on a scan, they’re on top of it.

“There is no value you can place on early detection of cancer, heart disease, etc.,” says Miller Levy, 51.

The umbrella term for this is longevity medicine, and it’s expanding rapidly. The core pitch: monitor your physiology like a hawk, take treatments on the cutting edge of science, and boost your odds of a longer, healthier life.

Efforts to boost life span go back to ancient Chinese herbal medicine (it still holds up). Today, many consumers aim to “biohack” their way to better health, or work with physicians on a longevity program that may include everything from advanced imaging to supplements, prescription drugs used off label, and other treatments aimed to turn back the clock.

Longevity medicine isn’t an officially recognized specialty. But it’s attracting practitioners from internal medicine to endocrinologists. And companies across the healthcare spectrum aim to capitalize.

GLP-1s are part of the longevity pitch, fueling growth for companies like Eli Lilly, Novo Nordisk, and Hims & Hers Health. Device and monitoring companies include DexCom, for glucose levels, and firms like Garmin that sell smartwatches with increasingly sophisticated biosensors.

Overall, “consumer driven” diagnostic testing is a growth sector, rapidly turning into a $4 billion market, according to Morgan Stanley, which recommends Quest Diagnostics as a thematic winner. The testing company says it’s seeing “double-digit customer repeat rates” at its consumer site questhealth.com.

For consumers in the do-it-yourself camp, biohacking is now as easy getting an Amazon.com delivery. Tests to track thyroid function and inflammation markers can be delivered to your doorstep with the paper towels or dog food. Peptides that sound like they’re named after Star Wars characters (Epitalon, GHK-Cu, BPC-157) are often pitched by influencers as longevity drugs.

Banks are angling in, too. Earlier this year, JPMorgan Chase’s Sapphire Reserve card offered a discount on membership with Function Health, a company promising to empower customers to live “100 healthy years.”

How much hard science backs all of this? It depends. On the longevity conference circuit, attendees enjoy cold plunges amid talks of plasma replacement therapy and microdosing GLP-1s. Clinical trials proving their benefits aren’t nearly as commonplace.

Investment capital is flowing in, though. Longevity Technology, a trade publication, calls 2026 a “breakout year” for longevity biotech, saying that total capital raised in the first quarter was up 56% year over year to $3.74 billion.

Miller Levy’s venture-capital firm, backed by veteran venture capitalist Alan Patricof, 91, is in the thick of it. Two of their investments—BetterBrain and Cenegenics—test for individuals’ biomarkers and offer consumers targeted plans to boost their brain health and extend their longevity, recommending activities like piano lessons or fish oil for the brain, or nutrition and exercise plans for better physiological health.

Despite the gray areas of longevity medicine, there can be tangible benefits for your health and personal finances.

Catching a cancer or heart condition early on could be lifesaving. If you have a better sense of how long you’ll live, you can claim Social Security at the optimal time and adjust your portfolio to match your expected life span. Your estate plan might look very different with a more data-driven approach to your health.

The flip side is that it’s hard to determine which products and services are likely to pay off medically versus the snake oil. Too much knowledge can also be harmful, leading to unnecessary tests and costs, and more anxiety than it’s worth.

“There’s a lot of progress, a lot of knowledge, and 10 times more noise,” says Dr. Nir Barzilai, president of the Academy for Health & Lifespan Research and board member of American Federation for Aging Research.

Here’s what to know.

Connecting the Data Dots
Longevity medicine is many things, from peptides to body scans and biometric devices like the Oura ring. Some of this comes cheap, but going all out can run up the tab sharply.

West Palm Beach, Fla.-based Radence, for instance, bills itself as an “elite membership” practice, offering patients a “360-degree look at your health data and what may be developing beneath the surface.” Its $50,000 a year membership (after a one-time, $50,000 enrollment fee) includes advanced biomarker panels, organ imaging, genetic analysis, microbiome profile, and wearables.

Memberships with recurring revenue streams are now a key business model. Function Health, for one, offers members upward of 160 lab tests a year for $365 and recently partnered with Equinox to give a discount to members of the gym. Function also acquired Ezra, a maker of diagnostic scans, last year. A competitor, Prenuvo, promises “the full picture of your health” through magnetic resonance imaging starting at $1,199 for a scan and core membership plan.

If there’s a common theme to all of this, it’s that more data are better than less. And proponents argue that it pays to monitor your biometrics, often in real time, so your physician or medical team can swoop in at signs of trouble.

It doesn’t cost much to get started. Wearables like a Garmin or Apple Watch can let you know how much rapid-eye-movement sleep you get, whether you have signs of sleep apnea, if your blood oxygen is too low, or if your heart is skipping a beat. Genetic tests can show your risk of Alzheimer’s disease, while other tests measure your telomeres—that’s the tip of the chromosome, whose length indicates biological age.

Artificial intelligence is helping to drive the expansion, as companies link test results to personalized recommendations based on users’ biological data.

Hims & Hers, an online purveyor of weight-loss and erectile dysfunction drugs, recently launched Labs by Hims & Hers, offering testing for biomarkers and a “doctor developed action plan” for up to $349 a year.

For most of these products, consumers have to pay out of pocket. Insurers generally aren’t paying for the tests or treatments offered in response to their results.

In a sense, the rash of at-home testing can be seen as a response to an expensive and often inaccessible health system, where patients often have trouble getting an appointment and spend a fortune after they get in the door.

Indeed, most of the new products and services sit outside of the traditional insurance system. Health plans typically don’t cover experimental or investigational treatments, according to AHIP, an insurers’ trade group. For them to do so, there would need to be evidence of a “substantial clinical benefit,” a spokesperson said.

In other words, there would have to be evidence linking test results to a treatment that has been proved to improve health, and many longevity interventions don’t have that backing.

Part of the issue is a vast gray market and lack of regulation. Purveyors of supplements aren’t required to prove effectiveness. Test results from federally certified labs must be accurate but not necessarily clinically meaningful or actionable. Outside of medications like insulin and semaglutide (both peptides), the FDA doesn’t evaluate the amino acid chains for long-term efficacy.

More broadly, the country’s regulatory framework reinforces a disease-centric approach. The Food and Drug Administration oversees drugs to treat diseases. The system also rewards treatment more than prevention; patients are more lucrative when they’re sick.

Some longevity proponents want aging classified as a disease, partly so the FDA would approve preventive treatments. Clinical trials are in the works; a major one aims to determine if metformin, now approved as a diabetes medication, can delay age-related diseases like cancer and dementia, and improve cardiac health.


Amid the uncertainty, longevity doctors view themselves—and their patients—as trailblazers. For now, the technology is being test-driven on a “population that can afford it,” says Dr. Julie Chen, chief medical officer for Radence, which uses AI to help sift through clinical studies. As the technology improves and costs fall, it’s likely to be more widely adopted, she says.

Which Tests Are Really Worth It?
If you’re unsure whether to pay for a battery of lab tests, consider the approach taken by Dr. Andrea Klemes: If it doesn’t have strong clinical trial backing, she doesn’t recommend it.

Klemes is chief medical officer at MDVIP, a network of concierge medicine practices. She scours the literature for diagnostic tools that show promise in clinical trials, and only a handful make the cut.

One good test, she says, looks for an enzyme called myeloperoxidase, which can indicate arterial inflammation. Most standard blood panels don’t include it, and insurance rarely covers it. But it’s a biomarker with clinical backing for impending heart attack risk, and she recommends it at MDVIP.

“We’re looking for things you can do something about,” she says.

MDVIP takes a cautious approach towards “liquid biopsy” cancer tests, a popular offering by many longevity firms. These tests might make sense for high-risk patients, Klemes says, but they can throw off false positives and often require follow-up testing to make a definitive diagnosis.

Other tests that aren’t part of the standard work-up include epigenetic and telomere tests, which aim to gauge a patient’s biological age, and full-body MRI scans, which can detect abnormalities that aren’t clinically significant but still prompt follow-up procedures like biopsies.

One of the best tests, she says, is low tech. Clinical studies tie grip strength to longevity in older adults, so she recommends that for MDVIP patients.

The Personal Finance Connection
If testing gives you a better sense of your longevity, you can plan accordingly. Say a test indicates that your chronological age is higher than your biological age—you’re a 60-year-old in a 50-year-old’s body. In that situation, it might make sense to assume you’ll live longer and save more to prepare. You might also decide to delay claiming Social Security until age 70 to get the maximum benefit.

Conversely, if you knew an incurable cancer would kill you at 65, you’d probably take Social Security at your earliest eligibility of 62. Since you wouldn’t have to worry about running out of money in old age, you might travel the world, buy a sports car, or gift an early bequest to heirs.

The problem, of course, is that tests results usually aren’t black and white. Most cancers are spontaneous and can’t be detected in a genetic test. Your biological age may be wonderfully low, but disease often shows up unannounced.

Alzheimer’s is another gray area. Genetic risk can be detected, but there’s no effective treatment or cure. You’re left to take your best shot at prevention.

That isn’t as hard as it might sound. A 2024 analysis found that about 45% of dementia cases are potentially preventable based on lowering risk factors like hearing loss, depression, and high cholesterol.

Bear in mind that knowledge about your genetic risks can be counterproductive, leading to excessive worrying for years. “You can track too much info, and it can make you anxious,” says Dr. Steven Lamm, medical director of NYU Langone’s Preston Robert Tisch Center for Men’s Health.

When it comes to supplements or over-the-counter peptides, don’t go overboard. Most of it is unproven, and some could even harm. There’s a belief that nutraceuticals—a portmanteau of nutrition and pharmaceutical—can’t hurt because they’re natural, but “poisons are natural,” Barzilai says.

High-Tech Superaging
Assuming cost is no object, and you can live with some bad or ambiguous news, it’s hard to argue against testing. The technology is advancing so fast, moreover, that there may be a payoff both in life span and “health span,” your time actually living without serious disease.

Mainstream consumers should ask hard questions, not just about medical benefits. Do you have the financial resources to live deep into your 80s, 90s, or beyond? And do you have a plan to address the many other facets of superaging, including the possible need for home care or assisted living? Loneliness, isolation from family, and depression can be particularly devastating for the elderly, and antidepressants only go so far.

Some physicians say these are good problems to have, provided they can be addressed. “I have patients that are 65, 75, 85, still working full time and contributing to society,” says Dr. Joseph Raffaele, Miller Levy’s physician in New York City. “That’s what longevity medicine is all about.”

What gets lost in the hype is that you can you do a lot on your own. You could measure your telomeres—or you could just exercise, eat well, not smoke, and avoid alcohol. Those low-cost changes go a long way: America could reduce illness by 50% on a population level through basic lifestyle interventions, Lamm says.

A study earlier this year suggests that less of our longevity is under our control than previously thought. Researchers at Israel’s Weizmann Institute of Science found that genes account for about half of human longevity—much more than prior estimates of less than 10%.

Nature be damned, tech entrepreneurs like Bryan Johnson are all in on biohacking. Based in Los Angeles, Johnson aims to be the first “prototype” human not to die. He has spent millions of dollars a year on his health, taking upward of 100 supplements a day, tracking hundreds of biomarkers, and eating precisely 2,250 chef-prepared calories a day. He has also taken stem cell infusions.

Johnson also sells longevity, pitching custom-made supplements and other products. Yet even he concedes that simple changes to lifestyle and diet can go a long way. “Most of longevity is behavioral change,” says Johnson. “You can’t buy it with money.”

Barron's : Japanese Stocks Are Bargains, Even After Big Gains

Japanese Stocks Are Bargains, Even After Big Gains
Value investors think the good times are far from over for the Japanese stock market. Here are stocks and funds to invest in now.

  • The Nikkei 225 has risen 18% this year, with the MSCI Japan index trading at under 18 times forward earnings, a discount to the S&P 500.
  • Shareholder reforms, strong manufacturing, and a $550 billion investment program with the U.S. are attracting investors to Japan.
  • Japan’s core inflation is 2% to 3%, shifting company pricing strategies and potentially moving $1.7 trillion of household cash into equities.

Japan has had more than its share of challenges lately, chief among them energy shortages, higher costs from the closure of the Strait of Hormuz, and questions about Prime Minister Sanae Takaichi’s ambitious fiscal spending plans.

That hasn’t stopped investors from snapping up shares of Japanese stocks. The Nikkei 225 is up 18% this year—and 47% over the past five years. Working in Japan’s favor are shareholder-friendly governance reforms in the private sector and increased demand for Japanese services and goods as nations race to revitalize manufacturing and reduce reliance on China.

Investors looking for value say there’s more to come.

Even after the latest gains, the MSCI Japan index trades at under 18 times forward earnings—a discount to the almost 21 times for the S&P 500. Analysts have boosted their earnings expectations for Japanese companies since the start of the year. After about a third of companies reported their results for the fourth quarter of fiscal 2025, which ended in March, Société Générale analysts noted that earnings growth averaged about 18%, suggesting full-year earnings per share growth of 7.5%.

U.S. Treasury Secretary Scott Bessent’s recent visit to meet with top Japanese officials, including Takaichi, highlights the opportunity ahead, especially for Japanese industrial companies that help the U.S. and other countries shore up critical supply chains. As part of its trade pact with the U.S., Japan committed to a $550 billion investment program to help fortify Western economies from reliance on—and competition from—China. The first projects have been directed at power generation, oil and gas, and critical minerals.

As the U.S. shifted into services over the past couple of decades, Japan preserved its manufacturing infrastructure, sometimes sticking with unprofitable operations. That manufacturing prowess is now increasingly valuable. Christian Heck, a fund manager and deputy head of value at First Eagle Investments, says the Japanese economy’s aging and shrinking population means it has been early in areas like factory automation, and can now take the skills it has honed abroad. “Any sort of reshoring or onshoring means you need highly automated factories. There isn’t enough labor, and labor is too expensive,” Heck says.

One of Heck’s cheaper holdings is SMC Corp., a world leader in pneumatics equipment manufacturing. The company’s 40% global market share is still growing—its business requires millions of parts, making it harder for rivals to break in. That has allowed SMC to generate ample free cash flow, high returns on invested capital and strong margins. The company has invested heavily recently to increase its capacity, which Heck thinks can deliver mid- to high-single-digit revenue growth over time and a stock return in the teens.

Japan also benefits from the push to find other sources of critical minerals and lessen reliance on China. About a decade ago, Japan discovered a large, deep-sea rare earth deposit that is considered the world’s third-largest high-quality, mineral-rich rare earth reserve. The deposit includes yttrium and dysprosium used in permanent magnets, clean-energy technologies, and advanced chemicals.

Japan has the infrastructure to develop these reserves and has recently outlined a plan to commercialize it, says Masakazu Takeda, co-manager of the Hennessy Japan fund. One potential beneficiary in Takeda’s portfolio: Shin-Etsu Chemical, a silicon wafer and PVC manufacturer, that also has a rare-earth business that could help commercialize the reserves. Though Takeda says the company’s role in building infrastructure was the draw, the rare-earth component is an added benefit.

Japanese companies are also taking a bigger role in the U.S. housing market. Sumitomo Forestry’s recent acquisition of Tri Pointe Homes makes it one of the top builders in the U.S. Sumitomo is looking to consolidate the fragmented U.S. housing market. Though Sumitomo’s shares have lagged behind the broader market as home buyers struggle with affordability in the U.S., Takeda says it’s a matter of when, not if, the market turns.

The dynamics at home also bode well for some companies. Japan is facing inflation for the first time in decades, with core inflation rising 2% to 3%, unfathomable a decade ago in the depths of Japan’s deflationary rout. Among the beneficiaries are banks and cash-rich companies that avoid higher borrowing costs and earn meaningful interest on their cash.

Inflation has another advantage. “Our companies have pricing power but have never used it because it was seen as un-Japanese to raise prices. Now, all of a sudden, it is acceptable,” says Heck. Hoshizaki, which makes ice makers for restaurants and other commercial uses and benefits from relatively stable demand, has increased prices several times since Covid after a 20-year period of no such hikes. “For the businesses we own, that mentality change—that price increases are socially acceptable—has been beneficial,” says Heck. “Pricing is a very important lever because it flows right through to the bottom line.”

At the same time, Japanese government borrowing costs have surged, with the 10-year yield hitting 2.75%, its highest point since 1997. The sharp move in the bond market reflects investor concerns that the Bank of Japan might be moving too slowly to deal with inflation exacerbated by Takaichi’s efforts to blunt the higher energy prices with fiscal stimulus.

Still, the government’s push for companies to start deploying their cash has attracted foreign investors, especially with the Tokyo Stock Market’s “naming and shaming” campaign targeting companies trading below price-to-book value. The exchange is now looking to send a stronger message by revising its corporate governance message to get companies to stop hoarding cash.

Roger de Bree, managing director and fund manager at Tweedy, Browne, invests with an eye for bargains, and sees Japan as a fertile place to invest. Koito Manufacturing, which makes lights for cars and laser safety systems, said in 2025 it would buy back 350 billion yen worth of shares. So far, the company has bought back 50 billion yen. That has boosted the stock, but the company still has room to do more. By his analysis, the company is currently trading at about 10 to 11 times next year’s expected earnings.

“The country is slow to adopt new things, partly because culturally it is slow-moving,” Takeda says. “There is always initial resistance to change. The flip side is that once momentum sets in, it can turn into a significant movement.”


Japanese policymakers have been intervening in the currency market to stem the slide in the Japanese yen. In a note to clients, Société Générale currency strategist Kit Juckes said the yen is likely closer to a recovery. Although the Bank of Japan kept rates at 0.75% at its last meeting, three board members dissented, and SocGen analysts expect the central bank to raise rates soon.

Several major brokerages allow investors to trade on the Japanese stock exchanges. But investors can also gain a foothold more easily in Japan with the iShares MSCI Japan exchange-traded fund or, for those worried the yen won’t shake off its weakness, the WisdomTree Japan Hedged Equity ETF.

A stronger yen could bolster confidence domestically, encouraging Japanese households to invest more at home. Already, Japan has offered nudges like expanding tax-exempt investment accounts to woo some of the $7 trillion, or half of Japanese households’ wealth, that has been parked in cash into equities.

Japanese retail investors have just 14% allocated to stocks. If they inch nearer to Europe’s 25%, Morgan Stanley estimates that could translate to $1.7 trillion in equity purchases. That’s about 20% of the market cap of Tokyo Stock Market Prime Exchange, which lists the biggest companies.

Barron's : SpaceX IPO Is a Game You Should Play at Your Own Risk

SpaceX IPO Is a Game You Should Play at Your Own Risk
The largest U.S. IPOs tend to underperform the market, with a not-insignificant share of those stocks delivering negative returns.

In a bygone era, an initial public offering was a way for investors to get in on the ground floor of a promising company. In 2026, it’s more like parachuting onto the roof.

When SpaceX goes public in June, the company is likely to carry a valuation approaching $2 trillion. It will probably raise a record $75 billion in the deal. CEO Elon Musk may become humanity’s first trillionaire. We’re way past start-up.

Thanks to a seemingly bottomless pool of funding, the most exciting companies can stay private for longer and go public at dizzying valuations. Artificial-intelligence rivals Anthropic and OpenAI, data platform Databricks, and payment processor Stripe are all candidates for so-called mega-IPOs at valuations of $100 billion or more if SpaceX’s offering goes well.

Bigger isn’t necessarily better, though. Historical data show the largest U.S. IPOs tend to underperform the market, with a not-insignificant share of those stocks delivering negative returns. And the coming wave of mega-IPOs presents more risks than usual: Private investors are licking their chops at the prospect of cashing in on long-awaited gains.


Even the savviest, most battle-tested investors may fear missing out. But SpaceX and its fellow IPOs won’t behave like normal stocks for months, if not longer, and trading promises to be choppy and unpredictable. Waiting out the chaos may not be exciting. It will be shrewd.

Facebook, now Meta Platforms, still holds the record for being the most highly valued U.S. company at the time of its IPO, with a market cap of $81 billion in May 2012. SpaceX could come public at more than 20 times that size—even larger than Meta is today.

The AI labs, meanwhile, are still conducting 12-figure private funding rounds of their own. OpenAI secured $122 billion at a $852 billion valuation in late March. Anthropic one-upped its rival the next month, fielding proposals from investors that would value it at as much as $900 billion, according to multiple reports.

Saudi Aramco is the lone historical corollary for IPOs of that size. It went public on Saudi Arabia’s stock exchange in 2019 at a valuation of $1.7 trillion.

“The only company that has done something at this scale was a state-funded oil company in one of the less transparent markets in the world,” says Avery Marquez, director of investment strategies at IPO research firm and fund sponsor Renaissance Capital. “There is really no relative scale.”

The record of the very largest IPOs is spotty at best. Excluding Cerebras Systems, the chip maker that completed its IPO a few weeks ago, 36 U.S. companies have gone public on a U.S. exchange with a market cap of $15 billion or more, according to FactSet. Only nine have beaten the S&P 500’s returns from their first-day closing price. Just 17 have generated positive returns at all.

Look down the list of winners and you’ll see tech luminaries like Google, now known as Alphabet (+15,500%), and Palantir Technologies (+1,347%). But for every Google, there’s a Lyft (-83%). And for every Palantir, there’s a UiPath (-85%). Some of the companies, such as telecom equipment maker Lucent Technologies and smartphone precursor Palm, have all but disappeared.

However you slice the data—narrowing in on tech companies, expanding to IPOs of any size, excluding the dot-com bubble—you’ll notice a pattern. On average, stocks spike on their first trading day but struggle to keep up the momentum over time. The 1,724 U.S. IPOs from 2011 through 2024 had an average first-day pop of 23%, according to data from Jay Ritter, a University of Florida professor dubbed Mr. IPO. Over the next three years, the newcomers lagged behind the market by 25 percentage points.

The trends are especially rough for companies that trade at a high premium to their revenue, suggesting big expectations for growth. Since 1980, issuers with trailing annual sales of at least $100 million and a price-to-sales ratio above 40 have seen an average three-year drop of 45% from their first day’s close.

SpaceX will be the next name in that data set. At an estimated market cap of $1.8 trillion, the company would trade at 93 times trailing sales.

“I think there’s a very good chance that these IPOs will jump on the first day of trading,” Ritter says. “And whether they go up or not, one thing that I’m certain about is the stock is going to be very volatile.”

Don’t expect the data to spook investors, many of whom have been waiting for years to invest in SpaceX. In fact, there are plenty of reasons to expect yet another explosive first-day gain in June.

To start, the hard numbers are genuinely impressive. SpaceX accounts for the majority of all orbital launches worldwide, and its use of recycled rockets has driven per-launch costs well below what the sector ever thought was possible. Starlink, its satellite broadband system, served 10.3 million customers by the end of March, generating profit margins on earnings before interest, taxes, depreciation, and amortization, or Ebitda, of 63% on $11.4 billion in revenue in 2025.

And if “innovative telecom business” is the floor for SpaceX stock, putting solar-powered data centers in space represents the stratosphere. Like many of Musk’s ideas, “orbital AI” seems straight out of a sci-fi novel, but the company is already attracting serious partners like Alphabet
GOOGL and Anthropic. At a time when data-center developers are scrambling for power and land, SpaceX is offering to eliminate the need for both.

The AI business, SpaceX says in its IPO prospectus, has a total addressable market of $26.5 trillion, nearly as large as the entire U.S. gross domestic product of $31.9 trillion.

Then there’s the hype: “SpaceX has been the most famous private company in the world, attached to one of the most polarizing public figures alive, and inaccessible to most investors for two decades,” explains Jake Miller, co-founder of Opto, a tech platform for private investing. “That’s a generational IPO story, not a normal one.”

For now, it’s also an unprofitable one. In the first quarter of 2026 alone, the company reported a $1.9 billion operating loss, driven by a $2.5 billion loss in the AI segment.

SpaceX didn’t respond to Barron’s requests for comment.

By all accounts, investors are pining for shares. SpaceX has yet to declare the size of its IPO offering, but it will likely be a single-digit percentage of the company’s total shares outstanding. The company plans to set aside much of that for retail investors, including those with accounts at Charles Schwab, Fidelity, Robinhood, and SoFi.

The retail focus makes sense given Musk’s unique pull among a certain set of self-directed traders, according to Marquez, who expects retail demand to be strong. One bracket higher, some high-net-worth investors are pitching the stock to their advisors, rather than the other way around.

“In all my years in this business, I’ve never had so many inbound inquiries on an IPO like this,” says Drew Freides, a UBS private wealth advisor who is optimistic about SpaceX in the long term but wants to see the valuation before recommending the stock to clients. “We spend a lot of time, you know, reining in clients and just being cautious.”

OpenAI and Anthropic are no less famous or exciting. The pair are locked in a warp-speed race to build the future of human technology, and they’re starting to generate significant cash. Anthropic said in May that it had hit a $30 billion annualized revenue run rate; earlier this year, OpenAI said its run rate had exceeded $20 billion.

Both companies declined to comment for this article. The Wall Street Journal reported last week that OpenAI is preparing to file a confidential IPO prospectus with regulators in the coming days. There are reasons for the pair to go public soon, particularly if SpaceX’s IPO is a success.


Training and running AI models is expensive, and the two companies are in constant need of capital. Public companies can use their stock to open the financing spigot quickly. Competition—for capital, a record valuation, or good old-fashioned bragging rights—is the other factor.

“There are no public AI companies,” Harrison Rolfes, a research analyst at PitchBook, says. “Whoever IPOs first becomes the market leader.”

The real winner of a mega-IPO isn’t necessarily the company or public investors, though. Private investors are the ones coming out on top.

Following the financial crisis, legislators designed the 2012 Jumpstart Our Business Startups Act to stimulate public markets. But the law also eased the path for private offerings, by allowing larger companies to keep their financials private. Under the JOBS Act, the threshold for requiring disclosure went from 500 shareholders to 2,000.

With less of a regulatory nudge, companies can soak up round after round of funding from investors looking for exponential returns. It helps that private markets are no longer the exclusive province of venture-capital firms. Institutions, family offices, and high-net-worth individuals are all getting in on the action. Some investors have access through special-purpose vehicles —a pooled secondary-market investment—that the companies themselves may not recognize as legitimate.

“If you pay close enough attention, you can find someone who can sell you some SpaceX,” says Tom Kerr, co-head of investments at private markets investment firm Hamilton Lane. (Kerr doesn’t advise going that route.)

Early investors often have astronomical gains on paper—SpaceX, for instance, was worth a measly $30.5 billion in 2018—but selling shares on the secondary market can get clunky. An IPO solves that problem, giving founders, employees, and other private shareholders an opportunity to sell shares at will. And make no mistake, investors will take at least some chips off the table.

Companies are already stating as much publicly. The London-listed Edinburgh Worldwide Investment Trust, which has had a stake in SpaceX since 2018, said in April it would propose a tender offer following the SpaceX IPO allowing shareholders in the closed-end fund to “crystallize” their returns. On an earnings call in February, Cannae Holdings CEO Ryan Caswell said the investment firm’s SpaceX stake “seems like it’ll be a source of cash for us over time.”

Lise Buyer, founder of IPO advisory firm Class V Group, says private-market investors are under pressure to provide liquidity to clients. “It’s hard to go out and raise new funds if you haven’t put any money back in the pockets of your previous investors.”

Others are exiting before the IPO even happens. Marc Lipschultz, co-CEO of embattled private-equity firm Blue Owl Capital, told investors in April that the company had realized roughly 10-times returns by selling about half of its SpaceX investment at a $1.25 trillion valuation.

To be sure, investors won’t be able to dump shares right away. Private shareholders typically have a six-month lockup period after an IPO during which they are prohibited from selling.

Issuers and their investment banks are increasingly engineering ways to reduce the cascade of stock at the six-month mark. Cerebras shareholders, for instance, will get a chance to convert and sell 84 million Class B shares in August, then another 87 million shares in September and October—all before six months pass in mid-November. SpaceX is getting similarly creative, with a portion of shares unlocking after the company’s second- and third-quarter earnings report. Another batch unlocks if the stock price reaches certain levels.

“At some point, you’re going to have a massive waterfall of stock that’s going to be coming to market,” says Ken Smythe, CEO of secondary investments firm Next Round Capital. “How the company manages that is going to be critical because there’s never been this amount of unlock at one time.”

Retail-trader personalities online have a warning for investors trying to buy from institutions: “You are the exit liquidity.” With mega-IPOs, that exit liquidity will likely include the index funds held by pension funds and retirement accounts.

Nasdaq rolled out a “fast entry” rule in May that shortened the waiting period for megacap stocks to be included in the Nasdaq 100 index to 15 trading days, down from as long as a year. S&P Dow Jones Indices has also proposed shortening its wait for S&P 500 inclusion to six months from 12 months. It could implement the rule just before SpaceX’s IPO.

Dozens of the world’s most popular funds are linked to these indexes and will likely be forced to buy recent mega-IPOs sooner than they would have before. This forced buying could create the demand early investors need to unload shares, facilitating an enormous wealth transfer from private markets to public markets.

“The insider is going to be able to cash out at this inflated price, but the index funds are going to be buying at this inflated price,” says Ben Schiffrin, director of securities policy at Better Markets, a consumer-focused advocacy group. “That seems, you know, not great for retail investors.”

On one hand, the automatic demand is helpful. If issuers like SpaceX can properly time lock-up expiries, they may be able to prevent huge selloffs when new shares become available. On the other hand, markets are in uncharted territory when it comes to the sheer volume of stock changing hands. Investors trying to ride the coattails of funds by buying SpaceX just before it gets included in the Nasdaq 100 or the S&P 500 may find themselves in a crowded trade.

“Once you get past those index inclusions, then where is the demand?” Jim Lebenthal, chief markets strategist at Cerity Partners, puts it. “I suspect that these companies will have a very long, profitable future as public companies, but there might be a little hiccup in the shares after they’re included in the indexes.”

It will be difficult to ignore the news when SpaceX starts trading in a few weeks. Those who don’t buy the SpaceX IPO could easily get the SpaceX FOMO instead.

Freides, the UBS advisor, says client inquiries are more about a fear of missing out and less about company fundamentals. “They feel like, ‘I should’ve been in this thing years ago. And why aren’t I in this, and how do I get in this? And I don’t care what it costs.”

Resisting the urge to chase the stock is the prudent move. Investors should expect wild, unpredictable swings in the first several months of trading, without the venture capital-like upside they would get from a smaller, younger company. SpaceX’s future may even include a merger with Tesla, further complicating the growth trajectory and stock upside.

To those tempted by the mega-IPOs, Lebenthal advised an admittedly old-fashioned approach: diversification and dollar-cost averaging.

“There are plenty of retail investors out there who are like, ‘I want to move all my chips on to OpenAI.’ Good luck, I wouldn’t do that,” he says. “You get some on the IPO? Great, save some dry powder for whatever may come next.”

IPOs the size of SpaceX, or indeed OpenAI and Anthropic, are essentially a new asset class altogether. Each quarter that passes after SpaceX’s IPO will offer new data on how the asset behaves. Patient investors get the benefit of seeing more quarterly results and gauging SpaceX’s progress toward justifying its valuation. Perhaps more importantly, they will see how both hype-driven investors and billion-dollar institutions react.

Another argument for patience: Investors who bought Meta after its first day of trading are up 1,474% today. Those who bought it six months later have booked gains of 2,454%.

IPOs get treated like the main attraction. Just remember that the real investment story is what happens next.

>>> What to look at today - 22th of Mayl 2026

Asian stocks rose for a second day to head for a weekly advance as investors rotated into a broader set of companies tied to the artificial intelligence buildout. MSCI’s Asian equities gauge climbed 0.7%. Japan’s Nikkei led regional gains with a 2.3% rally. SoftBank Group Corp. surged more than 11% in Tokyo, following gains in US-listed shares of chipmaking unit Arm Holdings Plc. Lenovo Group Ltd. climbed to a 26-year high in Hong Kong after reporting strong growth in AI-related earnings. US equity-index futures also edged up, with contracts on the Nasdaq 100 Index rising as much as 0.5% before paring the advance. Still, caution over geopolitics kept gains in check. Brent rebounded after three days of declines to rise above $104 a barrel, as statements by Iran on uranium and the Strait of Hormuz pared earlier optimism over progress in the negotiations with the US.
Technology shares have surged this year as investors poured into companies viewed as critical suppliers to the global AI expansion. The momentum has helped markets look past the conflict in the Middle East, lifting equities to record highs. Stock traders are now also chasing a wider array of beneficiaries as mainstream usage of AI creates demand for hardware beyond the most-advanced chips that companies such as Taiwan Semiconductor Manufacturing Co. make for Nvidia Corp. Themes emerging from an intensifying memory crunch and advances in robotics are also luring bids. Elsewhere, gold edged lower to about $4,530 an ounce. The yen hovered around the 159 level against the dollar, near its weakest level since April 30, as Japan’s key inflation gauge slowed by more than forecast.  Yen traders will be closely watching trading after Tokyo hours, where a lack of participants could exacerbate exchange-rate moves. They are also on alert for the risk of intervention on Monday, when holidays from London to New York are expected to reduce market liquidity. In more geopolitical news, Iran is discussing with Oman how to set up some form of a permanent toll system that will formalize its control of maritime traffic through Hormuz. President Donald Trump said the US wants the waterway to be open and free of tolls. US Secretary of State Marco Rubio said there were “some good signs” that a deal with Iran could be reached, adding that he expected Pakistani mediators to travel to Tehran, according to the Financial Times. Meantime, Iranian President Masoud Pezeshkian said “we will never back down” in talks.

Nikkei +2.29% Hang Seng +0.89% CSI +0.47% Shanghai +0.28% Shenzen +1.03%

Eur$ 1.1610 CNH 6.8017 CNY 6.7999 JPY 159.05 GBP 1.3425 CHF 0.7868 RUB 70.9506 TRY 45.7371 WTI$ 97.50 +1.16% Gold 4,526 +0.06% BTC 77,695 +0.06% ETH 2,135 -0.05%

S&P +031% Nasdaq +0.41% EuroStoxx +0.90% FTSE +0.42% Dax +0.85% SMI +0.65%

Macro :
- Musk’s Lieutenants Set for Billion-Dollar Fortunes on SpaceX IPO
- Turkey Looks to Calm Markets After Court Blow to Opposition

Keep an eye on :
- AMP IM : Amplifon Offers Up to 45.3m Shares: Terms
- AMS LN : H.B. Fuller Said to Bid Over £600 Million for AMS in Health Push
- ARM US : *ARM HOLDINGS ADRS CLOSE UP 16% IN BIGGEST GAIN SINCE MARCH
- §BII§B US : Biogen, Denali Phase 2b Luma Study Did Not Meet Endpoints
- BIRK US : Birkenstock Surges on Buyback Plan, Reiterated Guidance --> +19%
- BT/ LN : Bharti Seeks UK Support to Raise BT Stake: Reuters
- DECK US : Deckers Outdoor Rises After 4Q Beat, 2027 Net Sales Forecast (1)
- DTE GY : Deutsche Telekom to Build AI Platform for German Government
- ELUXB SS : Electrolux Announces Terms for SEK 9.06 Billion Rights Issue
- EL US : Estee Lauder and Puig End Merger Talks Without Agreement --> +10%
- XOM US : Exxon May Return to Venezuela, Ending a Long Fight With Its Leaders
- GTT FP : GTT Receives LNG Carrier Tank Design Order From Hanwha Ocean
- IMAX US : IMAX Shares Jump as WSJ Reports Company Is Exploring a Sale --> +15%
- INO US : Inovio Says VGX-3100 Phase 3 Trial Met Primary Efficacy Endpoint
- ML FP : Michelin: April Global Original Equipment Car Tire Market -6%
- NANO FP : Nanobiotix Offering Prices at $38.98/ADS, €33.60/Share
- NOVN SW : Generics drugmaker Sandoz calls for EU to probe alleged China dumping
- PNE3 GY : PNE Has Started Search for New Investor: Bond Prospectus
- PUIG SM : Estee Lauder and Puig End Merger Talks Without Agreement (2)
- QDT FP :
- RAND NA : LTM Offers to Buy Randstad’s Units in Europe, Australia
- REC IM : CVC, GBL Offer to Buy Recordati for €51.29/Share in Cash
- RL US : Ralph Lauren Jumps as Luxury Shoppers Spend at Full Price
- SHEL LN : Shell Set for Top Dutch Court Fight Over Call to Slash Emissions
- SOBI SS : Sobi Phase 3 Gout Treatment Study Met Primary Efficacy Endpoint
- SOI FP : Soitec Among Potential Stoxx 600 Additions, JPMorgan Says
- SPCX US : SpaceX Delays Starship Rocket Launch After Uncovering Issue
- SPCX US : Cursor Hits $3 Billion Annual Sales Rate Ahead of SpaceX Deal
- SPCX US : Musk’s Lieutenants Set for Billion-Dollar Fortunes on SpaceX IPO
- CFR SW : Richemont Launches Buyback Programme for 10 Million A Shares, Richemont FY Sales at Constant Exchange Rates Beat Estimates
- TIT IM : Telecom Italia: Mandatory Savings Share Conversion Took Effect
- UMG NA : Spotify, UMG Partner on Paid AI Remix Tool for Premium Users
- VK FP : Vallourec, Syngular Solutions Sign MOU for Bioenergy Projects

>>> Europe : Brokers Upgrades & Downgrades - 22th of May 2026

>>> Up
* Clariant Raised to Overweight at JPMorgan; PT 9.30 Swiss francs
* Generali Raised to Neutral at Oddo BHF; PT 40 euros
* Hill & Smith PT Raised to 3,400 pence at Peel Hunt
* NIO Inc. ADRs Raised to Buy at CMB International; PT $7
* Selvaag Bolig Raised to Buy at ABG; PT 41 kroner
* Spotify PT Raised to $600 from $540 at Jefferies
* Strabag Raised to Buy at Erste Group; PT 109.50 euros
* S&U UPGRADED TO BUY VS HOLD AT BERENBERG, PT 2,310P

>>> Down
* Elior Cut to Add at AlphaValue/Baader
* Evonik Cut to Underweight at JPMorgan; PT 14 euros
* IMCD Cut to Underweight at JPMorgan; PT 75 euros
* Lanxess Cut to Neutral at JPMorgan; PT 18 euros
* Lanxess Cut to Sell at Goldman; PT 13 euros
* Rio Tinto Cut to Neutral at BofA
* Sandvik Cut to Sell at Nordea; PT 315 kronor

>>> Initiation
* Barrick Mining Rated New Equal-Weight at Barclays; PT C$56
* BioNTech ADRs Rated New Market Perform at Bernstein
* CoreWeave Rated New Buy at GF Securities; PT $162
* Dellia Group Rated New Buy at SB1 Markets; PT 500 kroner
* FedEx Reinstated at Buy by Citi Before Freight Spin Off
* Freeport Rated New Overweight at Barclays
* Greencore Group Re-Initiated Buy at Peel Hunt; PT 300 pence
* Incyte Rated New Market Perform at Bernstein
* Jazz Pharma Rated New Market Perform at Bernstein
* LHV Rated New Buy at Erste Group; PT 4.40 euros
* Newmont Corp. Rated New Overweight at Barclays
* Nucor Rated New Overweight at Barclays
* Revolution Medicines Rated New Market Perform at Bernstein
* Tap Global Group Rated New Buy at Cavendish; PT 3.70 pence

>>> Call
* Delivery Hero Investment Case Changed on Uber Stake: Berenberg

>>> Stoxx 600 Pre-Market Indications

  • Renault (RNL TH) +2.1%
  • ASML (ASME TH) +2%
  • RENK Group (R3NK TH) +1.9%
  • Infineon (IFX TH) +1.9%
  • TUI (TUI1 TH) +1.9%
    • TUI Partners With Travel Booking Platform Omio
  • Deutsche Post (DHL TH) +1.9%
  • Pan African (RTZ TH) +1.8%
  • Lufthansa (LHA TH) +1.8%
  • Aixtron (AIXA TH) +1.7%
  • BP (BPE5 TH) -1%
  • Babcock (BW3 TH) -1.1%
  • K+S (SDF TH) -1.4%
  • IMCD (INX TH) -2.3%
    • European Chemicals ‘Sector Blues’ Returning, JPMorgan Says
  • Evonik (EVK TH) -2.8%
    • European Chemicals ‘Sector Blues’ Returning, JPMorgan Says
  • Puig (B1B TH) -14%
    • Estee Lauder-Puig Talks Collapse After Charlotte Tilbury Tension

>>> TradeGate Pre-Market Indications

DAX:
  • Infineon (IFX TH) +2.1%
  • Deutsche Post (DHL TH) +1.9%
  • SAP (SAP TH) +1.6%
    • NOTE: Yesterday, Deutsche Telekom to Build AI Platform for German Government
  • Deutsche Bank (DBK TH) +1.5%
  • Siemens (SIE TH) +1.5%
MDAX:
  • RENK Group (R3NK TH) +2.5%
  • Lufthansa (LHA TH) +2.2%
  • TUI (TUI1 TH) +1.9%
  • CTS Eventim (EVD TH) +1.9%
  • Thyssenkrupp (TKA TH) +1.7%
  • Evonik (EVK TH) -2%
    • European Chemicals ‘Sector Blues’ Returning, JPMorgan Says
SDAX:
  • Heidelberger Druck (HDD TH) +1.2%
  • Kontron (KTN TH) +1.1%